A high-throughput screening (HTS) assay was developed for identifying compounds with inhibitory effect on aphA, one of the key regulators positively controlling Vibrio cholerae pathogenesis. An inhibitory effect on aphA was expected to lead to attenuation in the secretion of the major pathogenicity factors of V. cholerae, cholera toxin and toxin co-regulated pilus. The plasmid construct pAKSB was developed with a kanamycin resistance (Km R ) gene under the control of the aphA-like promoter for conferring a Km R phenotype under aphA-expressing conditions. The HTS assay was performed to identify compounds with inhibitory effect on the growth of O139 V. cholerae MO10 carrying the construct pAKSB in growth medium containing Km (30 g ml À1 ), but not in its absence. Of 20 338 compounds screened, six compounds were identified to inhibit the pAKSB-induced Km R phenotype and these compounds caused transcriptional inhibition of aphA in V. cholerae O139 strain MO10 as well as variant V. cholerae O1 El Tor strain NM06-058. Of the three most active substances, compound 53760866 showed lowest half-maximal cytotoxicity in a eukaryotic cell viability assay and was characterized further. Compound 53760866 caused reduction in cholera toxin secretion and expression of TcpA in vitro. The in vitro virulence attenuation corroborated well in a suckling mouse model in vivo, which showed reduction of colonization by V. cholerae NM06-058 when co-administered with 53760866. The screening method and the compounds may lead to new preventive strategies for cholera by reducing the pathogenicity of V. cholerae.
INTRODUCTION
Vibrio cholerae is a Gram-negative, rod-shaped bacterium belonging to the genus Vibrionaceae. Strains belonging to the serogroups O1 and O139 are responsible for causing acute waterborne diarrhoeal epidemics known as cholera (Kaper et al., 1995) . The disease can cross continental boundaries to cause large pandemics. To date, human civilization has witnessed several pandemics; the current is the 7th pandemic, which began in 1961 and is still ongoing (Kaper et al., 1995; WHO, 2010) . In 2013, 47 countries reported a total of 129 064 cases of cholera including 2102 deaths, resulting in a case-fatality rate of 1.63 % (WHO 2014). In fact, cholera is still a major concern today with a high degree of morbidity and mortality among people living in developing or underdeveloped countries who lack access to safe drinking water and good hygienic conditions. A recent estimate shows that 36 % of the global population lacks access to improved sanitation facilities (Brocklehurst, 2014) . Oral rehydration therapy and antibiotics are available for cholera treatment, but a growing concern is the emergence of multidrug-resistant †These authors contributed equally to this work.
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Much attention has been attributed to the development or identification of new antimicrobial compounds or drugs that target component(s) of regulatory cascades (Clatworthy et al., 2007; Raju et al., 2012; Anthouard & DiRita 2013; Zahid et al., 2015) . A promising compound, 'virstatin', was identified, having the potential to attenuate CT expression by V. cholerae without altering growth of the target organism (Hung et al., 2005) . In an era when the occurrence of multidrug resistance is common among different human pathogens, identification of virulence-specific and safe drugs will be advantageous. Virulence inhibitors may have the potential to be employed in situations where an infection has not (yet) occurred and when vaccinations are not available or would not be able to build up a timely protection. To identify such virulence-specific active compound (s), the major impediment is non-availability of HTS assays appropriately designed with proper target gene(s)/phenotypes. The V. cholerae virulence-suppressive compound virstatin was identified by a screening assay (screening of 50 000 compounds) targeting reduction of CT expression, as CT is one of the major virulence factors of V. cholerae (Hung, Shakhnovich et al., 2005) . Virstatin was found to reduce expression of toxin co-regulated pilus (TCP), the other most important virulence factor of V. cholerae. Virstatin acts by inhibiting dimerization of the transcriptional activator ToxT (Shakhnovich et al., 2007a) . Further studies also showed that the presence of toxT alleles in non-O1, non-O139 V. cholerae resulted in virstatin resistance (Shakhnovich et al., 2007b) . New studies are emerging to predict potent inhibitors on the basis of in silico analysis on high-resolution X-ray cryptographic data on target regulatory proteins like ToxT of V. cholerae (Mondal et al., 2014) .
In the present study, we have developed a high-throughput screening (HTS) assay to identify compound(s) with inhibitory potential on aphA, a novel target upstream in the regulation of the pathogenicity of V. cholerae. It was assumed that inhibiting aphA expression will cause a negative impact on the expression of pathogenicity factors of V. cholerae. In this HTS assay, 20 338 compounds comprising different chemical groups, namely secondary metabolites isolated from myxobacteria, short linear and cyclic peptides, and synthetic small molecules, were screened to identify active compounds with potential to attenuate V. cholerae virulence.
METHODS
Strains and cultural conditions. The strains used in this study are listed in Table 1 . V. cholerae O139 strain MO10 (Nandy et al., 1999) carrying the construct pAKSB (see below) served as reporter strain during development of the HTS assay for identifying active compounds that have the potential to attenuate virulence phenotypes. For the construction of the reporter strain, WT MO10 was electroporated with the plasmid construct pAKSB containing ampicillin resistance (Amp R ) for selection and kanamycin resistance (Km R ) under the control of the promoter of the aphA-like gene of V. cholerae. V. cholerae O1 El Tor variant clinical strain NM06-058 (Sergeev et al., 2014) was also included to validate the effectiveness of the compounds on this variant (Raychoudhuri et al., 2008) , which is currently prevalent in many parts of the world. For virulence-inducing conditions, strains were grown in AKI (Iwanaga & Yamamoto, 1985) , pH 7.4 at 37 C, and nutrient broth [NB (peptone 15 g l ] pH 8.0 was used for virulence-suppressive conditions. For the HTS assay, the reporter strain MO10 pAKSB was grown in AKI with or without 30 µg kanamycin (Km) ml
À1
. Ciprofloxacin (Cip; 100 µM) was used as a positive control in the HTS assay while medium containing 1% DMSO served as negative control. Assessment of the compounds to attenuate virulence was performed under AKI growth conditions.
Generation of plasmid construct pAKSB with Km R phenotype under control of the aphA-like gene promoter. The 200 bp upstream region of the aphA-like gene of N16961 (Heidelberg et al., 2000) (GenBank accession no. AE003852) and the 816 bp Km R structural gene from pUC4K were amplified separately with high-fidelity Taq polymerase (AmpliTaq Gold, Applied Biosystems). A PCR fragment-joining method was used for fusing these amplicons to generate a 1039 bp fragment where the Km R structural gene was under the control of the aphAlike gene promoter. Briefly, a reverse primer targeting upstream of the aphA-like gene and a forward primer of the Km R structural gene were designed with 15 bases of complementary identity towards the 5¢ end of the primers (Table 1) . Both amplicons were mixed together at equimolar ratio, and PCR was performed with a combination of aphA-F1 and Km-R1 primers to generate a PCR-ligated amplicon where the promoter of the aphA-like gene was fused upstream of the Km R structural gene. The amplified product was cloned into the EcoRV site of pBluescript SK+ after adding one additional T overhang. Ready-to-use electro-competent Escherichia coli host strain DH10B (Invitrogen) was used to generate transformants that were selected on 50 µg ampicillin (Amp) ml À1 plates. The transformants were characterized initially by PCR to confirm the presence of the appropriately sized insert of the cloned fragment followed by nucleotide sequence analysis to confirm the regularity of the sequence. The construct, named pAKSB, was electroporated into the O139 strain MO10 (sensitive to both Amp and Km) and the transformants were selected on plates containing 50 µg Amp ml À1 .
Compound libraries. Three commercially available libraries were either completely or partially used for the screening: (i) the LOPAC collection of pharmacologically active compounds with 1408 entities (Sigma); (ii) the Echaz Microcollection with 7304 compounds (EMC Microcollections); and (iii) the CDI collection with approximately 17 000 compounds (Chemical Diversity Lab), a commercially available collection assembled by members of the ChemBioNet consortium (Lisurek et al., 2010) . Three additional unique libraries of the Helmholtz Centre for Infection Research (HZI) were also included: (i) the NCH collection consisting of 154 secondary metabolites isolated from myxobacteria (Gerth et al., 2003) and with known antimicrobial activities (Weissman & Müller 2009);  (ii) the library Various Sources (VAR), containing at the time of this study 1936 synthetic organic molecules that were provided by various collaborators; and (iii) the peptide library containing 1045 short linear or cyclic peptide sequences synthesized at the HZI (Tegge et al., 2007) . All test compounds were utilized as stock solutions in DMSO.
HTS of the compounds. This assay was carried out in either 96 or 384-well clear, flat-bottom microtitre plates (MTPs) using MO10 pAKSB grown in 100 µl or 50 µl (96-or 384-well plate, respectively) AKI-Km (30 µg ml
) medium with an OD 600 of 0.1 (1Â10 8 c.f.u.). Addition of the compounds was made into individual wells from DMSO stock. Plates were incubated statically in a humid atmosphere for 24 h at 37 C, and growth of the cells was recorded (OD 600 ) using a Fusion Universal Microplate Analyzer (PerkinElmer). Screening was performed with a total of 20 338 compounds in one fixed concentration between 20 and 50 µM. Accurate dispensing into the wells of the MTP was achieved with the help of a pipetting robot (equipped with either a pintool or pipetting tips). As negative and positive controls, DMSO (1 %) and Cip (100 µM) were used in duplicate, respectively. Z-values were calculated using the negative and positive controls (Zhang et al., 1999) . Compounds of the initial screening that caused at least 50 % reduction of growth were tested in a second run at the same concentration. In order to identify and to eliminate active compounds with non-specific growth-suppression activities, the same assay was repeated in AKI medium without Km. The compounds that exhibited growth-inhibitory properties in AKI-Km but not in AKI medium without Km were selected for further characterization.
Growth inhibitory half-maximal concentration (g-IC 50 ) against MO10 pAKSB. The g-IC 50 values of the active compounds were determined by growing reporter strain MO10 pAKSB in 96-well MTP in the presence of serially diluted compounds. Seed inoculum (100 µl) with an OD 600 of 0.1 (1Â10 8 c.f.u.) was added to each of the wells containing appropriately diluted active compounds in either AKI or AKIKm media. Active compounds were used at concentrations from 0.1 µM to 100 µM. The plates were incubated statically for 24 h at 37 C, and growth of the cells was recorded (OD 600 ) using a Fusion Universal Microplate Analyzer. Based on the extent of growth corresponding to different concentrations of a compound, the g-IC 50 value was determined by visual inspection of the growth curves generated with the program Excel (Microsoft) after normalization to the DMSO negative control. The g-IC 50 value of a compound was separately determined for AKI and AKI-Km media.
GM 1 assay to estimate CT. V. cholerae O1 El Tor variant strain NM06-058 was used as a test strain to estimate CT production when grown in the presence of various amounts of the active compounds following methodologies as described by Patra et al. (2012) . Briefly, the strain was grown in AKI for 18 h in the presence of serially diluted active compounds, intact cells and debris were pelleted by centrifugation and cell-free culture supernatants containing CT were collected. A GM 1 ELISA was performed with the cell-free supernatants to quantify the secreted CT. Readings were taken in an automated ELISA reader with filter set to 492 nm after background corrections at 620 nm (Multiskan EX, Thermo Scientific). Varied dilutions of known amounts of purified CT (Sigma) were included in each of the assays to generate a standard curve for the estimation of CT in the culture supernatants. Wells containing cell-free supernatants of cultures grown in the presence of up to 1 % DMSO served as negative controls. Amounts of CT secreted by V. cholerae were expressed as pg (ml culture) À1 per unit opacity at 600 nm. Quantitative real-time PCR (qRT-PCR). V. cholerae O1 variant El Tor strain NM06-058 was used to detect the effects of compounds vz0852, vz0761 and 53760866 on transcription of the virulence genes (ctxA and tcpA) and the regulatory element aphA. Cells were grown for 12 h in 2 ml AKI in the presence of the compounds vz0852 at 3.1 µM, vz0761 at 12.5 µM and 53760866 at 25 µM concentration, respectively. Following 12 h of growth, OD 600 was determined, the concentration adjusted to~5Â10 8 c.f.u.
(1 OD 600 corresponded to~1Â10 9 c.f.u. ml
) and a twofold volume of RNAprotect Bacteria reagent (Qiagen) was added. The mixture was incubated for 5 min at room temperature and the cells were recovered as pellets by 10 min of centrifugation at 5000 g. Total RNA was extracted using the TRIZOL method (Patra et al., 2012) . Briefly, total RNA thus extracted was further treated with RNase-Free DNase (Qiagen) to remove contaminating traces of DNA, if present. A reverse transcription was carried out with 1 µg of isolated RNA obtained from cells grown under different cultural conditions and in the presence of random hexamer. For this, a RevertAid H Minus First Strand cDNA Synthesis kit (Fermentas) was used and cDNA synthesis was performed in a PCR machine (model 2720, Applied Biosystems). This cDNA was utilized for qRT-PCR analysis with SYBR Green I Master mix (Life Technologies) in a HT Fast real-time PCR machine (Applied Biosystems). The gene-specific primers used in the real-time PCR assay are listed in Table 1 . Results were recorded and normalized with respect to C t values for recA and compared to respective values obtained from cells that were grown in the absence of any active compound. Comparative data were expressed as a relative percentage of the target mRNA. Cells grown separately in the presence of 1 % DMSO served as a negative control.
Cytotoxicity assay. The mouse fibroblast cell line L929 was utilized to investigate the cytotoxicity of the active compounds in an MTT assay according to a standard protocol (Mosmann, 1983) , with some modifications (Sasse et al., 2002) . Varied amounts of the compounds were used to detect the effects of cytotoxicity and to determine half-maximal inhibitory concentration (c-IC 50 ). Cells were observed following incubation for 24 h to detect acute toxicity. Incubation was continued for 5 days mainly to record the inhibition of cell proliferation and sub-acute toxicity.
Western blot analysis. V. cholerae NM06-058 was grown in AKI, pH 7.4 at 37 C for 18 h under static conditions. Cells were grown in media containing 1 % DMSO or varied amounts of compound 53760866. Cells were harvested, washed, and lysate was prepared using SDS-PAGE sample buffer. The lysate was separated by SDS-PAGE (15 % gel) and transferred to PVDF membranes using a Transblot apparatus (Bio-Rad). A polyclonal anti-TcpA serum was raised against the peptide KVSADEAKNPFTGTAMG with commercial support (Thermo Scientific). The blots were subsequently probed with polyclonal rabbit anti-TcpA serum followed by treatment with horseradish-peroxidaseconjugated goat anti-rabbit IgG. The blots were developed with 3,3¢-diaminobenzidine in the presence of hydrogen peroxide.
Mouse intestinal colonization assay. Three groups with six mice each (5-6-day-old Swiss albino mice) were used. Each mouse received a dose of orogastric inoculation with~6Â10 5 c.f.u. of V. cholerae NM06-058 in 100 µl medium containing (i) in the first group 0.5 % DMSO only as control, (ii) in the second group 100 µM compound 537760866 (10 nmol in total) or (iii) in the third group 50 µM of 537760866 (5 nmol), with repetition of this dose after 3 h (second and third groups also contained 0.5 % DMSO from compound addition). Mice were sacrificed post-18 h of challenge, intestinal homogenates were generated and dilutions of these were plated to estimate recovery c.f.u. from each mouse (Patra et al., 2012) . Colonization potential was defined by the fold increase as the ratio of recovery counts to that of the feeding dose. Statistical relevance was calculated according to Welch's two-sample t-test.
RESULTS
Characterization of construct pAKSB conferring a conditional Km R phenotype in V. cholerae MO10
The pAKSB construct was developed that contained the Km R structural gene under the control of the aphA-like gene promoter of V. cholerae N16961. Presence of the construct in the V. cholerae O139 reporter strain MO10 resulted in an Amp R phenotype. The AKI condition promotes optimal expression of the virulence factors by O1 El Tor and O139 strains in vitro and thus this condition was considered to favour aphA expression (Lin et al., 2007) . In contrast, lowered expression of aphA was considered in the NB culture condition that suppresses virulence factors in vitro. Therefore, it was assumed that the conditional Km R phenotype would be induced in MO10 pAKSB (Km R under the aphA-like gene promoter) under the AKI condition, to serve as a surrogate marker for the expression of aphA, and as such the Km R phenotype would be abolished in the NB culture condition. Validation of the conditional Km R phenotype was established by observing the growth of MO10 pAKSB in AKI but not in NB when bothmedia contained 30 µg Km ml À1 (Table 2 ). The parent strain MO10 failed to grow in the presence of Km but grew well in the absence of 
HTS assay to identify active compounds
The new HTS assay was developed to screen active compounds from six different libraries consisting in total of 20 338 compounds. After optimizing screening parameters, growth inhibitory assays were performed using the MO10 pAKSB indicator strain. The Z-values of the initial screen were between 0.5 and 0.9, indicating reliable performance of the assay (Zhang et al., 1999) . The threshold for the selection of active compounds in the initial screening was defined as a growth reduction of more than 50 % in Km-containing media. The small NCH collection of 154 compounds had on average the most active molecules (statistically, 45.5 per 1000). The VAR library consists of molecules with predominantly unknown activities and had 19.1 antibacterial compounds per 1000 molecules. The other sources contained rather low amounts of active compounds, with the LOPAC collection scoring at 2.8 per 1000. This compound collection contains several antimicrobial agents that are in clinical use, which were reliably identified in the assay. The new HTS assay identified 56 active compounds with growth-inhibitory properties of V. cholerae in AKI containing Km. None of these compounds were reported previously to have bacterial growth inhibitory properties. Any compound with inhibitory potential on the promoter of the aphA-like gene will result in a loss of the Km R phenotype of MO10 pAKSB in the AKI condition. Thus, repeat assays were performed with the 56 growth inhibitory compounds in the absence of Km in AKI growth medium. Fig. 1 shows that compounds in certain wells (Fig. 1a , marked by circles) failed to display growth inhibition in the assay with AKI growth medium (absence of Km) (Fig. 1b) , whereas other compounds (Fig. 1a, b , marked by squares) caused growth inhibition in both the presence and absence of Km.
The analysis identified six active compounds which caused growth inhibition of MO10 pAKSB in AKI-Km but not in AKI media at the same concentration. The chemical structures of these six compounds are shown in Fig. 2 . The virulence inhibitor virstatin could not be used as a positive control for the inhibition of aphA, because its target is localized downstream of this gene.
Characterization of active compounds
The six active compounds were from the VAR collection, but from two different providers. They have in common a heterocyclic five-membered pyrazole (vz0761 and vz0852), thiazole (53760866 and 53761430) or oxazole (53761172 and 53761188) ring to which one or two further aromatic systems are linked, plus halogens. For none of these six active compounds have antibacterial activities previously been described. The database SciFinder (ACS) was scanned for compounds with structure similarities. Among the compounds that displayed at least 70-80 % structural similarity to the six active compounds, no antibacterial activities could be identified. Non-antibacterial functionality of these six active compounds matched well as all these compounds failed to exert anti-V. cholerae growth activities when tested at levels between 20 and 50 µM.
Reassessment of the six active compounds identified was made to reveal their growth inhibitory potential, if any, at higher concentrations on O139 indicator strain MO10. Growth inhibitory potential of these compounds at higher concentrations was evident, and g-IC 50 values in AKI medium varied widely. The g-IC 50 values of these compounds are presented in Table 3 . Comparative analysis showed lower g-IC 50 in AKI-Km as compared with the AKI growth condition. A marked reduction of the g-IC 50 values in the AKI-Km condition may be due to compound-mediated inhibition of the Km R phenotype under the control of the aphA-like promoter. The g-IC 50 values ranged between 6 and 100 µM. In AKI without Km the g-IC 50 values ranged between 38 and >>100 µM. The inhibitory index of these compounds was estimated as the ratio of g-IC 50 in the absence of Km in the culture medium to that of the same compound in the presence of Km in the culture medium. Based on the inhibitory index values, the three most active compounds, namely vz0761, vz0852 and 53760866, were identified. Similarly, g-IC 50 values were also determined against the study strain NM06-058 in MuellerHinton broth and these were 27, 61 and >>100 µM for the compounds vz0761, vz0852 and 53760866, respectively. ND, not determined. *Ratio of amount required (>50 µM, >100 µM and >>100 µM was considered as 50 µM, 100 µM and 200 µM, respectively) for 50 % reduction of growth in absence and presence of Km in growth media.
The cytotoxicity potential (c-IC 50 ) of these compounds was evaluated in an MTT assay using the mouse fibroblast cell line L929. Expectedly, the c-IC 50 values were higher after 24 h of incubation as compared with 5-day observations. Summarized results are presented in Table 3 . The three most active compounds (vz0761, vz0852 and 53760866) showed quite different cytotoxicity, with 53760866 displaying the lowest activity.
By employing the OSIRIS Property Explorer software (an online tool provided by www.openmolecules.org) for the most promissing compound, 53760866 a partition coefficient between n-octanol and water (logP) of 3.27 and further very drug-like properties with an overall drug score of 0.83 (on a scale of 0 to 1) were predicted. For compounds vz0761 and vz0852, high toxicity risks and overall drug scores of only 0.04 and 0.05, respectively, were calculated. These toxicity predictions correspond well with our experimental findings (Table 3) . Compound 53760866 thus appeared most promising from the in silico prediction as well as from the experimental data obtained in this study. Virulence inhibitors that are designed to reduce the secretion of bacterial toxins in the intestine will preferentially be applied orally and do not need to be taken up systemically. The methods of medicinal chemistry (Dörwald, 2012) may be utilized to further improve the activity of the active compounds while reducing toxic effects that may become evident in future in vivo investigations.
Impact of the most active compounds on CT secretion by V. cholerae O1
The ability of V. cholerae to secrete CT in vitro was assessed by GM 1 ELISA. The variant El Tor O1 strain (Raychoudhuri et al., 2008) NM06-058, a representative of the presently circulated biotype, was used for this assay. Table 4 shows that in the absence of any active compound (in the presence of 1 % DMSO), NM06-058 produced 36 ng of CT (unit opacity) À1 ml À1 in the AKI condition known for optimal expression of El Tor and variant El Tor biotypes (Ghosh-Banerjee et al., 2010) . Assays were performed in parallel with two different concentrations of active compounds. It is evident from Table 4 that the presence of the active compounds caused reduction in the secretion of CT by V. cholerae as compared with the DMSO control. The highest concentration of the compound used in the assay was based on 25 % of the amount required for g-IC 50 as determined separately for NM06-058. Expectedly, virstatin also showed a reduction in CT secretion.
Impact of the most active compounds on virulence genes (ctxA and tcpA) and regulatory element aphA transcripts An assessment was made to determine the inhibitory potential of the three most active compounds on the transcription level of ctxA, tcpA and aphA, which are involved in pathogenicity or regulation of pathogenicity in V. cholerae. The qRT-PCR analysis of the relative mRNA content was estimated after normalization with the values for the housekeeping gene recA. In the presence of the active compounds vz0761, vz0852 and 53760866 at 12.5, 3.1 and 25 µM, respectively, the relative transcript levels of the target genes ctxA, tcpA and aphA dropped below 50 % as compared with the DMSO control (Fig. 3) . A similar inhibitory effect was obtained with virstatin for the ctxA and tcpA transcripts. However, virstatin failed to exert any inhibitory effect on the aphA transcript level as compared with the DMSO control, as expected. These results indicated that the most active compounds identified in this study had either a direct influence on the expression of aphA or acted further upstream of this virulence gene activator. 
Impact of compound 53760866 on TcpA expression and mouse intestinal colonization
Compound 53760866 showed the lowest cytotoxicity among the three most active compounds (Table 3) (Fig. 5) . In fact, presence of the compound caused~80 % reduction of colonization. In a separate experiment, two doses with concentrations of 50 µM (5 nmol each) of the compound were given separated at an interval of 3 h. A similar level of inhibition to that of the single dose of 100 µM was obtained (P values for single dose application 4.033Â10 -5 and for two applications 3.896Â10
-5
).
DISCUSSION
Expression of CT and TCP has been shown to be linked with quorum sensing (QS) systems, and the presence of multiple QS systems has already been reported in V. cholerae (Camara et al., 2002) , which proceed simultaneously and have different regulatory functions, e.g. virulence gene expression, biofilm formation or protease production (Jobling & Holmes, 1997; Miller et al., 2002; Hammer & Bassler, 2003) . The central regulator, which all three QS systems have in common, is HapR. HapR regulates negatively the expression of aphA and thereby inhibits expression of the virulence genes ctxA and tcpA, and thus connects the QS system with virulence gene expression (Kovacikova & Skorupski, 2002) . Considering that virulence regulation in V. cholerae is highly complex and linked to other regulatory pathways including QS, the index gene aphA has the potential to work as a positive master regulator. With this background, a novel HTS assay has been developed in order to identify compounds that suppress V. cholerae virulence by linking reduced aphA expression to growth suppression. The selection of aphA in this HTS was based on the fact that the transcription factor AphA (i) is the master regulator of QS at low cell density (LCD) (Rutherford et al., 2011) , (ii) modulates index virulence gene expression, CT and TCP (Kovacikova & Skorupski, 1999) , (iii) controls nearly 300 genes at LCD which include flagella synthesis, type III secretion system, pilus production, etc. (Rutherford et al., 2011) and (iv) is present and conserved among V. cholerae strains. The plasmid construct pAKSB was developed to confer conditional Km R under in vitro virulence-inducing conditions (AKI), which served as an index for the expression of aphA. The reliability of the assay was established by confirming the conditional expression of the Km R phenotype in the AKI culture condition, which is known to stimulate CT and TCP expression by V. cholerae in vitro, but not in NB, pH 8.5, a virulence-repressing condition ( Table 2) . Application of the optimized HTS assay resulted in the identification of six active compounds with the potential to attenuate V. cholerae virulence from a total of 20 338 compounds. The g-IC 50 values of the six compounds were markedly different when compared between AKI and AKI-Km conditions (Table 3 ). The differences can be considered as an eloquent testimony of the Km R phenotype being linked to an inhibitory effect on the aphAlike gene promoter. Among the six active compounds, vz0761, vz0852 and 53760866 were found to be the most potent by their high inhibitory index (Table 3) . Results from a real-time PCR assay confirmed that the inhibitory effects of these three compounds were indeed linked to a reduction of aphA transcription in V. cholerae (Fig. 3) . Transcriptional analysis also confirmed concomitant reduction of the ctxA and tcpA transcripts in the presence of these compounds in the growth media (Fig. 3) , which corroborates well with the aphA-dependent inhibition of ctxA and tcpA expression at the transcriptional level (Kovacikova et al., 1999) .
Of the three most active compounds, 53760866 displayed the lowest toxicity in a eukaryotic cell-based assay (L929 cells) and was therefore characterized further. The compound 53760866 mediated transcriptional inhibition of the index virulence genes (ctxA and tcpA), resulting in a reduction of CT and TcpA expression (Table 4 , Fig. 4 ). The relevance of our in vitro observation was extended to an in vivo evaluation. A suckling mouse colonization assay showed that 53760866 can effectively reduce intestinal colonization when co-administered with V. cholerae strain NM06-058 (Fig. 5) . A similar extent of the inhibitory effect was evident between the regimen of a 100 µM single dose and two separate 50 µM doses 3 h apart (P<0.05 in both cases). This observation may be due to the stability of the compound within the host, although further characterizations are needed to gain conclusive evidence. Another limitation of our study is that the mechanism of inhibition of aphA transcription by 53760866 is not clear. The mechanism by which this potent chemical compound diminishes expression of aphA may be either by down-regulation of qrr small RNA transcription or by activation of HapR. These details are to be elaborated in the future.
In conclusion, we report the development of a HTS assay targeting altered expression of aphA as an index to identify V. cholerae virulence-suppressive compounds. Successful application of this new HTS made it possible to identify compound 53760866 with V. cholerae virulence-suppressive potential. The structure of the compound can provide a lead or serve as a focal point for appropriate modifications by the methods of medicinal chemistry for synthesizing new derivatives with better activities and reduced toxicities. Such compounds may be useful in reducing the pathogenicity of V. cholerae, especially in situations where the inoculum is low, thus providing species-specific protection on a short time-scale without the need to apply broadly acting antibiotics that could perturb the normal intestinal microbiome.
